All issues
Volume 25 (2010)
- Issue 6 Pages 552-
- Issue 5 Pages 448-
- Issue 4 Pages 362-
- Issue 2 Pages 94-
- Issue 1 Pages 8-
Volume 25, Issue 2
Displaying 1-6 of 6 articles from this issue
- |<
- <
- 1
- >
- >|
Feature articles “Target therapy against cancer:its basics and clinical application” Editor : Tomonori Habuchi
-
Yasufumi Kaneda2010 Volume 25 Issue 2 Pages 94-102
Published: 2010
Released on J-STAGE: June 15, 2010
JOURNAL FREE ACCESSCancers remain difficult to treat despite recent advances in cancer therapy, including new surgical options and advances in chemotherapy, radiotherapy and gene therapy. Treatment is aimed at controlling advanced and metastatic cancers and preventing recurrence. A number of promising new chemotherapeutic agents have been developed and, to reduce the side effects of chemotherapy, tumor-selective delivery vectors have been also developed. However, it is impossible to kill all the cancer cells by anti-cancer reagents. Thus, cancer immunotherapy is gaining interest. Although current immunotherapy can reduce, delay, or prevent tumor recurrence, many tumors still progress due to the development of mechanisms to avoid recognition and elimination by the immune system. Therefore, it is expected that immunotherapy might be used to eradicate residual cancer cells following therapy to reduce tumor volume. A number of studies suggest that both tumor regression and anti-tumor immunity are required for complete tumor eradication. To achieve both tumor regression and anti-tumor immunity without causing serious side effects, tissue-targeted drug delivery vectors with beneficial adjuvant properties will be required in the future.View full abstractDownload PDF (494K) -
Masanori Noguchi2010 Volume 25 Issue 2 Pages 103-109
Published: 2010
Released on J-STAGE: June 15, 2010
JOURNAL FREE ACCESSThe field of cancer vaccines is currently in an active state of clinical investigation. Human papilloma virus vaccine has been approved as a prophylactic cancer vaccine, while Oncophage (heat shoch protein-peptide complex) was recently approved in Russia for a certain stage of kidney cancer, although to date none has been approved in Japan or the USA. We reviewed recent clinical trials of several different types of cancer vaccine. There have been slow but substantial advances in peptide vaccines and dendritic cell-based vaccines with regard to both clinical response and immunological markers.
A personalized approach to boost immune responses, the addition of chemotherapy to overcome robust cancer and the changing of endpoints from tumor reduction to overall survival seem to be the three key elements for the development of the therapeutic cancer vaccines. Therapeutic cancer vaccine therapy has undergone wide clinical trials for urological cancer, and it is expected to become the fourth therapeutic method following surgery, radiotherapy and chemotherapy.View full abstractDownload PDF (536K) -
Toshiyuki Yoneda2010 Volume 25 Issue 2 Pages 110-119
Published: 2010
Released on J-STAGE: June 15, 2010
JOURNAL FREE ACCESSBone is a fertile soil in which bone-stored growth factors are continuously released into bone marrow as a consequence of osteoclastic bone resorption that takes place as an initial step of bone remodeling. This fertile bone microenvironment facilitates cancer cell survival and proliferation in bone. Cancer cells in turn influence bone microenvironment by producing varieties of cytokines which affect the proliferation and differentiation of bone cells including osteoclasts and osteoblasts. Disruption of this vicious cycle between cancer cells and bone will lead the development of novel selective mechanism-based therapeutic interventions for bone-colonized cancers.View full abstractDownload PDF (996K) -
Masamichi Nishio2010 Volume 25 Issue 2 Pages 120-125
Published: 2010
Released on J-STAGE: June 15, 2010
JOURNAL FREE ACCESSStrontium(89Sr)chloride which is a radiopharmaceutical is effective for multiple bone metastatic pain. 89Sr acts like a calcium metabolism, and it accumulates selectively to the accelerated bone metastatic portion.
The physical half life of 89Sr is 50.5 days, and the nuclide emits a pure beta ray. Because the maximum energy of this beta ray is 1.49 MeV(100%) and the range in the organization is an average of 2.4 mm (a maximum of 8 mm), the energy is almost self-absorption and few influences around the people.
We review the outline of the 89Sr treatment in present and suggest the use of this drug in future.View full abstractDownload PDF (439K) -
Noriyasu Fukushima, Shinya Kimura2010 Volume 25 Issue 2 Pages 126-133
Published: 2010
Released on J-STAGE: June 15, 2010
JOURNAL FREE ACCESSMolecular biology and genetic engineering have succeeded in leading the development of molecular target agents, which specifically target to the genes inducing carcinogenesis and the proteins relating to tumor growth. Conventional anti-tumor agents inhibit not only cancer but also normal cells, while molecular target agents inhibit basically only cancer cells. Thus, molecular target agents are very promising in cancer treatment.
Actually, ABL tyrosine kinase inhibitor, imatinib mesylate has dramatically improved the prognosis of chronic myeloid leukemia patients and become a first choice within a few years after the initiation of clinical use. In addition to imatinib mesylate, a lot of molecular target agents for hematological malignancies have been developed. Although molecular target agents are hopeful, there still remain a lot of problems such as resistance to the agents, drug lag and expensive prices that reflect increasing developmental costs, etc.View full abstractDownload PDF (400K) -
lessons learned from renal cell carcinomaNorihiko Tsuchiya, Tomonori Habuchi2010 Volume 25 Issue 2 Pages 134-142
Published: 2010
Released on J-STAGE: June 15, 2010
JOURNAL FREE ACCESSWe are facing a dramatic shift from cytokine therapy to molecular targeted agents in the therapeutic strategy for advanced renal cell carcinoma. Molecular targeted agents used in renal cell carcinoma, tyrosin kinase inhibitors, mTOR inhibitors, and anti-VEGF antibody, inhibit tumor growth mainly though anti-angiogenic activity. Those agents have different profiles of adverse events and sometimes induce unexpected serious events, although having a strong anti-tumor growth. To ensure maximum therapeutic effect, a team approach involving multi-disciplinary staffs becomes more important than ever.View full abstractDownload PDF (556K)
- |<
- <
- 1
- >
- >|